Moreau, P., Hulin, C., Perrot, A., Arnulf, B., Belhadj, K., Benboubker, L., Béné, M. C., Zweegman, S., Caillon, H., Caillot, D., Corre, J., Delforge, M., Dejoie, T., Doyen, C., Facon, T., Sonntag, C., Fontan, J., Mohty, M., Jie, K., Karlin, L., Kuhnowski, F., Lambert, J., Leleu, X., Macro, M., Orsini-Piocelle, F., Roussel, M., Stoppa, A., van de Donk, N. W. C. J., Wuillème, S., Broijl, A., Touzeau, C., Tiab, M., Marolleau, J., Meuleman, N., Vekemans, M., Westerman, M., Klein, S. K., Levin, M., Offner, F., Escoffre-Barbe, M., Eveillard, J., Garidi, R., Ahmadi, T., Krevvata, M., Zhang, K., de Boer, C., Vara, S., Kampfenkel, T., Vanquickelberghe, V., Vermeulen, J., Avet-Loiseau, H., & Sonneveld, P. (2021). maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial. Lancet oncology, 22(10), 1378–1390. http://access.bl.uk/ark:/81055/vdc_100144486874.0x000015